...
nvs-img

Novartis AG ADR, Common Stock

NVS

NYQ

$98.075

+$0.97

(1%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$193.47B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
16.8883
Volume info-icon
This is the total number of shares traded during the most recent trading day.
724.91K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
3.86%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.51
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$92.35 L
$120.92 H
$98.075

About Novartis AG ADR, Common Stock

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameNVSSectorS&P500
1-Week Return-1.27%-2.12%-2.22%
1-Month Return-5.8%-3.42%0.07%
3-Month Return-16.24%-11.13%3.71%
6-Month Return-8.16%-5.74%8.04%
1-Year Return-0.03%3.97%26.32%
3-Year Return20.24%1.05%29.42%
5-Year Return8.84%34.37%83.36%
10-Year Return21.79%97.88%185.56%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue48.68B49.90B52.88B51.83B46.66B[{"date":"2019-12-31","value":92.06,"profit":true},{"date":"2020-12-31","value":94.37,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.02,"profit":true},{"date":"2023-12-31","value":88.24,"profit":true}]
Cost of Revenue14.43B15.12B15.87B15.49B12.47B[{"date":"2019-12-31","value":90.91,"profit":true},{"date":"2020-12-31","value":95.3,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.6,"profit":true},{"date":"2023-12-31","value":78.6,"profit":true}]
Gross Profit34.25B34.78B37.01B36.34B34.19B[{"date":"2019-12-31","value":92.55,"profit":true},{"date":"2020-12-31","value":93.97,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.2,"profit":true},{"date":"2023-12-31","value":92.38,"profit":true}]
Gross Margin70.37%69.70%69.99%70.12%73.27%[{"date":"2019-12-31","value":96.04,"profit":true},{"date":"2020-12-31","value":95.12,"profit":true},{"date":"2021-12-31","value":95.53,"profit":true},{"date":"2022-12-31","value":95.7,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses25.17B24.63B25.32B27.14B24.42B[{"date":"2019-12-31","value":92.71,"profit":true},{"date":"2020-12-31","value":90.72,"profit":true},{"date":"2021-12-31","value":93.28,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.96,"profit":true}]
Operating Income9.09B10.15B26.95B9.20B9.77B[{"date":"2019-12-31","value":33.72,"profit":true},{"date":"2020-12-31","value":37.67,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":34.13,"profit":true},{"date":"2023-12-31","value":36.25,"profit":true}]
Total Non-Operating Income/Expense(791.00M)(1.22B)(17.04B)(208.00M)(1.14B)[{"date":"2019-12-31","value":-79100000000,"profit":false},{"date":"2020-12-31","value":-122100000000,"profit":false},{"date":"2021-12-31","value":-1704100000000,"profit":false},{"date":"2022-12-31","value":-20800000000,"profit":false},{"date":"2023-12-31","value":-113800000000,"profit":false}]
Pre-Tax Income8.94B9.88B26.14B8.37B9.12B[{"date":"2019-12-31","value":34.2,"profit":true},{"date":"2020-12-31","value":37.79,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":32.03,"profit":true},{"date":"2023-12-31","value":34.9,"profit":true}]
Income Taxes1.79B1.81B2.12B1.42B551.00M[{"date":"2019-12-31","value":84.62,"profit":true},{"date":"2020-12-31","value":85.28,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":66.82,"profit":true},{"date":"2023-12-31","value":26,"profit":true}]
Income After Taxes7.15B8.07B24.02B6.96B8.57B[{"date":"2019-12-31","value":29.76,"profit":true},{"date":"2020-12-31","value":33.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":28.96,"profit":true},{"date":"2023-12-31","value":35.69,"profit":true}]
Income From Continuous Operations7.15B8.07B24.02B6.96B8.15B[{"date":"2019-12-31","value":29.76,"profit":true},{"date":"2020-12-31","value":33.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":28.96,"profit":true},{"date":"2023-12-31","value":33.95,"profit":true}]
Income From Discontinued Operations4.59B----[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income7.15B8.07B24.02B6.96B14.85B[{"date":"2019-12-31","value":29.75,"profit":true},{"date":"2020-12-31","value":33.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":28.95,"profit":true},{"date":"2023-12-31","value":61.82,"profit":true}]
EPS (Diluted)5.285.786.296.126.90[{"date":"2019-12-31","value":76.52,"profit":true},{"date":"2020-12-31","value":83.77,"profit":true},{"date":"2021-12-31","value":91.16,"profit":true},{"date":"2022-12-31","value":88.7,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NVS
Cash Ratio 0.50
Current Ratio 1.11
Quick Ratio 0.90

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NVS
ROA (LTM) 10.59%
ROE (LTM) 28.79%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NVS
Debt Ratio Lower is generally better. Negative is bad. 0.58
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.42

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NVS
Trailing PE 16.89
Forward PE 11.82
P/S (TTM) 3.87
P/B 4.47
Price/FCF 35
EV/R 4.27
EV/Ebitda 10.81
PEG 2.88

FAQs

What is Novartis AG ADR share price today?

Novartis AG ADR (NVS) share price today is $98.075

Can Indians buy Novartis AG ADR shares?

Yes, Indians can buy shares of Novartis AG ADR (NVS) on Vested. To buy Novartis AG ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NVS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Novartis AG ADR be purchased?

Yes, you can purchase fractional shares of Novartis AG ADR (NVS) via the Vested app. You can start investing in Novartis AG ADR (NVS) with a minimum investment of $1.

How to invest in Novartis AG ADR shares from India?

You can invest in shares of Novartis AG ADR (NVS) via Vested in three simple steps:

  • Click on Sign Up or Invest in NVS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Novartis AG ADR shares
What is Novartis AG ADR 52-week high and low stock price?

The 52-week high price of Novartis AG ADR (NVS) is $120.92. The 52-week low price of Novartis AG ADR (NVS) is $92.35.

What is Novartis AG ADR price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Novartis AG ADR (NVS) is 16.8883

What is Novartis AG ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Novartis AG ADR (NVS) is 4.47

What is Novartis AG ADR dividend yield?

The dividend yield of Novartis AG ADR (NVS) is 3.86%

What is the Market Cap of Novartis AG ADR?

The market capitalization of Novartis AG ADR (NVS) is $193.47B

What is Novartis AG ADR’s stock symbol?

The stock symbol (or ticker) of Novartis AG ADR is NVS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top